Analysis 4.5. Comparison 4: Infliximab vs biosimilar (mixed/low disease activity at baseline), Outcome 5: Total adverse events.... Analysis 5.1. Comparison 5: Subcutaneous CT-P13 and purine analogues vs intravenous CT-P13 and purine analogues (active disease population with clinical response at baseline), Outcome